ArticleHaematologica2024

Belantamab mafodotin: an important treatment option for vulnerable patients with triple class exposed relapsed and/or refractory multiple myeloma.

Maria Victoria Mateos et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.